An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy

McGough, Sarah F.; Shamas, Natasha; Wang, Jue; Jaber, Mahmoud; Swarup, Binay; Zumofen, Marie-Hélène Blanchet; Lautié, Bertrand; Parreira, Joana; Wei, Michael C.; Shewade, Ashwini

doi:10.1182/blood-2022-159640

Blood

2022

DOI: 10.1182/blood-2022-159640

|View full text |Cite

An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy

Sarah F. McGough¹,

Natasha Shamas²,

Jue Wang³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…McGough SF et al [ 3 ]. conducted an external control cohort study based on real world data from US patients with r/r FL who received third-line or later treatments and met the eligibility criteria of the pivotal phase 2 trial leading to mosunetuzumab approval.…”

mentioning

confidence: 99%

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting

2023

View full text Add to dashboard Cite

Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for patients with relapsed or refractory (R/R) follicular lymphoma. The approval was based on results from an international, multicenter, phase 2 trial in patients with relapsed or refractory (R/R) follicular lymphoma following at least 2 prior lines of systemic therapy. Mosunetuzumab demonstrated remarkable efficacy with an overall response rate of 80% and complete response rate of 60%. Here we provided an overview of the latest clinical data on mosunetuzumab in lymphoma presented at the 2022 ASH Annual Meeting.

show abstract

mentioning

confidence: 99%

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting

2023

View full text Add to dashboard Cite

show abstract

Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States

Matasar,

Sanchez Alvarez,

Parisé

et al. 2024

Journal of Medical Economics

View full text Add to dashboard Cite

Mosunetuzumab for the treatment of follicular lymphoma

Labanca,

Martino,

Vigna

et al. 2024

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy

Cited by 5 publications

References 0 publications

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting

Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States

Mosunetuzumab for the treatment of follicular lymphoma

Contact Info

Product

Resources

About